Voglibose Tablets

This product is an oral hypoglycemic drug. Its mechanism of hypoglycemic effect is to inhibit the activity of a-glucosidase in the small intestinal wall cells, delay the degradation of ingested carbohydrates, and thus reduce postprandial blood sugar levels.

The main ingredient of this product is voglibose, and its chemical name is ()-1L-[1(OH),2,4,5/3]-5-[2-hydroxy-1-(hydroxymethyl)ethyl]amino-1-carbon-(hydroxymethyl)-1,2,3,4-cyclohexylfuran. Molecular formula: C10H21NO7, molecular weight: 267.28.

Improve postprandial hyperglycemia in diabetics. (This product is suitable for patients who have not seen significant effects from diet therapy and exercise therapy, or who have not seen significant effects from oral hypoglycemic drugs or insulin preparations in addition to diet therapy and exercise therapy.)

Generally, adults take 0.2 mg (1 tablet) orally 3 times a day before meals. If the therapeutic effect is not obvious, the dosage can be increased to 0.3 mg (1.5 tablets) after sufficient observation.

1 Serious side effects 1) Hypoglycemia may occur when used in combination with other diabetes drugs (less than 0.1-5%). In addition, there are reports that hypoglycemia may occasionally occur without other diabetes drugs (less than 0.1%). This product can delay the digestion and absorption of disaccharides. If hypoglycemia symptoms occur, sucrose should not be given, but glucose should be given for appropriate treatment. 2) Abdominal distension and increased intestinal gas (less than 0.1-5%) may occur. Due to the increase in intestinal gas, intestinal obstruction-like symptoms may occasionally occur (less than 0.1%). Observe thoroughly and take appropriate measures such as stopping the drug if symptoms occur. 3) Severe liver dysfunction accompanied by jaundice, increased GOT, and GPT may occasionally occur (less than 0.1%). In addition, there are reports that fulminant hepatitis has occurred with similar drugs (acarbose) (less than 0.1%), so observe thoroughly and take appropriate measures such as stopping the drug if abnormalities occur. 4) When administering the drug to patients with severe liver cirrhosis, due to the worsening of hyperammonemia and impaired consciousness (frequency unknown) caused by constipation, etc., bowel movements should be carefully observed, and appropriate measures such as stopping the drug should be taken immediately if any abnormality is found. 2 Other side effects 1) Digestive system: diarrhea, soft stools, abdominal borborygmi, abdominal pain, constipation, loss of appetite, nausea, vomiting, heartburn (incidence rate is less than 0.1-5%), stomatitis, thirst, abnormal taste (less than 0.1%), 2) Allergic symptoms Note 1): rash, itching (incidence rate is less than 0.1%), 3) Liver: increased GOT, GPT, LDH, g-GTP, ALP (incidence rate is less than 0.1-5%), 4) Psychoneural system: headache, dizziness, staggering, drowsiness (incidence rate is less than 0.1%), 5) Others: paralysis, facial edema, blurry eyes, fever, fatigue, weakness, hyperkalemia, increased serum amylase, decreased high-density lipoprotein, sweating, hair loss (incidence rate is less than 0.1-5%), Note 1) If these conditions occur, the drug should be discontinued.

The following patients are prohibited from taking this medicine: 1. Patients with severe ketosis, diabetic coma or pre-coma. They are not suitable for taking this medicine because they must use infusion and insulin to quickly adjust high blood sugar; 2. Patients with severe infection, patients before and after surgery or patients with severe trauma. They are not suitable for taking this medicine because they need to adjust blood sugar by injecting insulin; 3. Patients with a history of allergy to the ingredients of this product; 4. Pregnant women, parturients and lactating women should use this medicine with caution.

Precautions during pregnancy and lactation: Use with caution in pregnant, postpartum and lactating women.

Precautions for combined use 1. When using diabetes drugs (such as sulfonamides and sulfonylureas, biguanides, insulin preparations, insulin sensitizers) together: When using insulin and sulfonylureas together, there have been reports of hypoglycemia. Therefore, when using the above drugs together, the possibility of hypoglycemia should be considered and the drug should be administered cautiously from a low dose. 2. When using diabetes drugs together with drugs that enhance or reduce their hypoglycemic effects: 1) Drugs that enhance the hypoglycemic effect of diabetes drugs (beta-blockers, salicylic acid preparations, monoamine oxidase inhibitors, fibrate hyperlipidemia treatment agents, warfarin, etc.) 2) Drugs that reduce the hypoglycemic effect of diabetes drugs (epinephrine, adrenocortical hormones, thyroid hormones, etc.) When the above drugs are used together with this product, the interactions recorded in the precautions for using diabetes drugs together should be noted, and full attention should also be paid to the effects of this product's delayed sugar absorption effect.

Sealed and stored in a dry place at room temperature.

0.2 mg

Nanjing Hicin Pharmaceutical Co., Ltd.

• Founded in:

  2003-01-15

• Address:

  No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone

• Tax NO.:

  913201927453675877

• Registered Funds:

  120 million yuan

• Website:

  Log in to view

• Email:

  Log in to view